Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. - Test2 - elhamkhani - TriplyDB

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

http://www.wikidata.org/entity/Q34060890

about

Human polyomavirus reactivation: disease pathogenesis and treatment approaches Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis Lymphotoxin and TNF: how it all began-a tribute to the travelers Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science Tailored therapy for severe asthma Structural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody Infliximab Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab Infliximab.A rare case of supraventricular tachycardia induced by Infliximab: a case report.TNF-alpha is required for the attraction of mesenchymal precursors to white adipose tissue in Ob/ob mice.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Anti-TNF agents in Crohn's disease.TNF-alpha antagonists for the treatment of Crohn's disease.Current use of biologicals for the treatment of spondyloarthropathies.Infliximab treatment for Crohn's disease Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy.The effect of infliximab on patients with ulcerative colitis in Korea.Immunotherapeutic approaches to inflammatory bowel diseases.Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.Biologics in the management of psoriasis.Blockade of TNF-α rapidly inhibits pain responses in the central nervous system.How does infliximab work in rheumatoid arthritis?Bone marrow stem cells and stromal cells in autoimmune cytopenias.

P2860

Q21285083-06F39278-6549-47F1-A026-AC2DB32A7AEC Q24619923-420D38A5-6020-42F4-87BC-79EF2740028C Q24801075-C1315DF4-69C8-459E-9E15-9B3CB637E15A Q26749017-B7FFE98C-7290-47F1-AE86-4463DDF4C3A2 Q26767247-91801504-463A-4C31-B111-6CE2CCF36A5D Q26849811-F974DB06-E0ED-4D8D-B530-FD6B670BFA44 Q26865649-7B4DFFDA-B4E6-4DC1-868D-4DC49E83AF86 Q26995510-97B58C5D-FAFE-45ED-B17C-1E4642C5121A Q27016035-AE49B299-170C-46C8-B403-B92094962883 Q27676857-6EA5E08E-67EB-4084-ABBA-FE98D5BD4909 Q28222748-BDF8985B-FE97-4AB4-8D90-F4A46D77967F Q30307998-1531970C-B148-4BDA-A06F-10E71CD7F3BC Q33158097-8FF047A2-9829-4B94-AF31-EF14B67E47B5 Q33408808-41DFF41C-E291-4793-AC98-3DF76CB62BBF Q33522232-334A057A-B63D-4EDF-A91A-984D11AE026E Q33574857-57E0AD6F-589A-48AE-B37E-378D0F6E7489 Q33613493-73A8D25C-6322-40BB-BA64-8138678E4BA9 Q33629320-01E18BC7-4E39-4314-9571-42EA29662381 Q33641577-122FD8D9-3273-4855-8B81-3F5B391AFC07 Q33641909-48D82E27-A668-406D-B7A5-FDF4B31A13AA Q33782349-2686BF21-B8FD-4B76-A177-59B79C23CA24 Q33798966-04F20DF4-548C-45FF-B9FF-735DBE66D95F Q33904308-4F88765B-8D00-4F46-A86A-712FA217D7A2 Q33910076-B8DA86E9-1B46-4268-A470-4EFF574EEBCE Q33964687-17A13BAD-66F4-4C5B-BDA4-CB3ECB150A97 Q34027648-B93D238F-32F4-4962-A35B-726AAA743BA6 Q34074674-9383CCC5-862F-4D44-ACE8-18AEB90142C3 Q34182047-495A6CEA-AC22-44A9-A5A4-D00105898D31 Q34240751-FE338B40-FD65-401C-9D01-84C32AF32BE7 Q34292153-C6FE8E3C-78AA-4E94-B1D9-8661668F667D Q34316206-B3B0F8AE-6055-44D2-9DC7-C02C16F8278E Q34336510-32627BE2-7074-4855-BA36-976B2A0BD319 Q34378785-45CB971D-E450-4FCD-B7AF-660D7E60BF38 Q34451989-BDD6B7E4-08FF-43A1-AB56-01997DD2FD61 Q34476049-AA8BD44D-DD30-4889-96B3-2264FF432574 Q34560557-948E1687-17BB-4C1E-8DF9-1F67EFBD895F Q34620257-34FF7D19-D57F-40A0-8385-B0137C88019F Q34621522-074AD499-11A6-462F-AB8C-32B26094BB16 Q34731292-502D577A-CE75-4C32-93F1-0E43F7D4958E Q34769871-F5190EEF-3370-4E9D-90E6-3A44083B59EE

P2860

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

http://www.wikidata.org/entity/Q34060890

description

1993 nî lūn-bûn

@nan

1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@ast

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@en

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@nl

type

label

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@ast

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@en

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@nl

prefLabel

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@ast

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@en

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@nl

P1433

Q34060890-F8F2CA23-3B6C-4EDA-BEA3-7FE0A009DA58

P1476

Q34060890-EC7B19B9-0D13-481C-AC20-9BD9F3310B2A

P2093

Q34060890-3576E690-61BD-4BF2-8116-05C529BB9AD6

Q34060890-4185CEC0-81AA-4958-81B8-164E2324381C

Q34060890-8EE76AC4-A2C7-40DB-9465-ECCB466C7A20

Q34060890-91CDD152-8A76-430B-A385-D22FE908B8BB

Q34060890-9D2FABA9-690D-4A62-98C1-F455A05CDF1D

Q34060890-BC306C49-53A5-44B9-A1E5-1D8E0BE3CC62

Q34060890-C4C0F580-586B-4394-AFFD-ADFEF398B129

Q34060890-D2A6D075-4CAA-4BB3-908D-033342AE15AF

Q34060890-D3BDB224-AF59-4A71-8485-45A685A7B7F5

Q34060890-EE1BDC4D-B24D-46FF-8E07-7940A89278AE

P304

Q34060890-52D47F5D-158F-4820-B10B-985D387C342E

P31

Q34060890-9A6C6923-15E9-4453-8308-D79A2D9A3034

P356

Q34060890-B3EB5A68-673F-4BD4-AF45-F116E7BBA282

P433

Q34060890-C801C892-1889-4BEF-83D7-AB6599193680

P478

Q34060890-731D7586-B5F6-46FB-9C11-CD19140BE967

P577

Q34060890-8F2308D5-B41A-47DB-887E-EFE0F8001FBA

P698

Q34060890-FD868AE5-A5B2-4BAA-9ADA-BCDCAA142FBE

P921

Q34060890-3E77A6F7-6A50-40CF-A7D6-72B625AE0528

Q34060890-789926CB-DB8A-4947-8FF9-C7BC0647C790

Q34060890-8539BD8F-1797-4109-956A-C614E8FE1F03

P356

0161-5890(93)90106-L

P1433

Molecular Immunology

P1476

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

@en

P2093

Daddona P

http://www.w3.org/2001/XMLSchema#string

Knight DM

http://www.w3.org/2001/XMLSchema#string

Le J

http://www.w3.org/2001/XMLSchema#string

McDonough M

http://www.w3.org/2001/XMLSchema#string

Moore MA

http://www.w3.org/2001/XMLSchema#string

Scallon B

http://www.w3.org/2001/XMLSchema#string

Shealy D

http://www.w3.org/2001/XMLSchema#string

Siegel S

http://www.w3.org/2001/XMLSchema#string

Trinh H

http://www.w3.org/2001/XMLSchema#string

Vilcek J

http://www.w3.org/2001/XMLSchema#string

P304

1443-1453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/0161-5890(93)90106-L

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

1993-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8232330

http://www.w3.org/2001/XMLSchema#string

P921